Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
SAN FRANCISCO–(BUSINESS WIRE)–May 31, 2022– Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, GA. In a recorded presentation, the company will highlight results from a recent survey of individuals living with congenital adrenal hyperplasia (CAH) to assess their perceptions around glucocorticoid treatment regimens and glucocorticoid-associated side effects.
Details are as follows:
Title: (P079) A Survey of Patients Living with CAH Assessing Their Perceptions on Glucocorticoid Regimen and Glucocorticoid-Associated Side Effects
Session Date & Time: 1:00p.m. – 3:00p.m.ET on June 11, 2022
Presenter: Dr. Chris N. Barnes
Authors: Dr. Chris N. Barnes, Dr. Rosh Dias, Melodie Feather and Nina Sherpa-Pine
The poster will be on display during the conference in ENDO 2022’s virtual poster hall starting on June 11, at 10:00 a.m. ET. Access more information about ENDO 2022 at https://endo2022.endocrine.org.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
Source: Spruce Biosciences